Internal Medicine, Endocrinology, Diabetes, & Metabolism · Stockton, CA
NPI
1609840479
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
0
Medicare group memberships
Hospitals
3
Hospital affiliations
930 N Center St
Stockton, CA, 95202
Phone (209) 948-3000
Medicare paid, 2024
$229K
3,278 services
Medicare patients, 2024
716
Average age 72
Drug cost, 2024
$4.6M
14,388 prescriptions
Company payments, 2025
$2,290
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anan A Faidi was code 99214 (office e&m - established), 1,159 times for 492 patients. In total Anan A Faidi billed 3,278 services in 17 codes, and Medicare paid $229K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,159 | 492 | $92.84 | $108K |
| 99442 Telephone Services | Office | 377 | 226 | $64.27 | $24K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 346 | 132 | $50.08 | $17K |
| 99454 E&M - Miscellaneous | Office | 303 | 84 | $39.97 | $12K |
| 77080 Standard X-ray | Office | 255 | 255 | $40.71 | $10K |
| G0506 Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 139 | 139 | $49.41 | $6,868 |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 139 | 83 | $108.63 | $15K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 113 | 75 | $38.28 | $4,326 |
| 93922 Duplex Scan - Extremity Arteries | Office | 107 | 107 | $61.02 | $6,529 |
| 99453 E&M - Miscellaneous | Office | 83 | 83 | $16.63 | $1,380 |
| 99489 Chronic, Principal, and Transitional Care Management | Office | 78 | 44 | $57.84 | $4,512 |
| 99213 Office E&M - Established | Office | 73 | 64 | $57.41 | $4,191 |
| 99205 Office E&M - New | Office | 57 | 57 | $165.85 | $9,453 |
| 99204 Office E&M - New | Office | 23 | 23 | $119.82 | $2,756 |
| 93880 Duplex Scan - Extracranial Arteries | Office | 18 | 18 | $127.24 | $2,290 |
By year: 2022 $186K for 2,310 services; 2023 $172K for 2,121 services; 2024 $229K for 3,278 services.
Medicare prescription drug claims, 2024
In 2024, the drug Anan A Faidi prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,227 prescriptions and refills. In total Anan A Faidi wrote 14,388 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,227 | 2,763 | 289 | $16K |
| Ozempic Semaglutide | 1,038 | 1,260 | 164 | $1.2M |
| Jardiance Empagliflozin | 928 | 1,479 | 201 | $817K |
| Glimepiride Generic | 745 | 1,667 | 187 | $7,413 |
| Atorvastatin Calcium Generic | 724 | 1,729 | 204 | $7,234 |
| Metformin Hcl Generic | 719 | 1,662 | 191 | $5,974 |
| Tradjenta Linagliptin | 515 | 735 | 92 | $348K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 508 | 845 | 152 | $35K |
| Pioglitazone Hcl Generic | 394 | 946 | 112 | $4,712 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 360 | 579 | 92 | $50K |
| Ibandronate Sodium Generic | 313 | 689 | 91 | $7,480 |
| Januvia Sitagliptin Phosphate | 282 | 446 | 63 | $229K |
| Alendronate Sodium Generic | 273 | 559 | 68 | $1,875 |
| Humalog Mix 75-25 Kwikpen Insulin Lispro Protamin/Lispro | 240 | 296 | 46 | $65K |
| Lisinopril Generic | 235 | 582 | 70 | $1,588 |
Brand drugs: 6,535 claims; generic drugs: 6,692 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anan A Faidi $2,290 ($2,290 in general payments such as food, travel and fees) from 23 companies. The largest payer was Lilly USA, LLC with $358.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 22 | $358 |
| Amgen Inc. AMGN | 16 | $269 |
| Xeris Pharmaceuticals, Inc. | 15 | $256 |
| Novo Nordisk Inc NVO | 16 | $254 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $154 |
| Almatica Pharma LLC | 6 | $145 |
| Beta Bionics, Inc. BBNX | 5 | $135 |
| GlaxoSmithKline, LLC. GSK | 2 | $108 |
| Madrigal Pharmaceuticals MDGL | 4 | $97.76 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $82.02 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.